
Annual report 2022
added 03-29-2023
Chembio Diagnostics Cash Flow 2011-2026 | CEMI
Annual Cash Flow Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-12.7 M | -30.9 M | -18.9 M | -9.06 M | -11.8 M | -5.03 M | -6.7 M | 1.79 M | -3.82 M | 2.28 M | 761 K | 2.27 M |
Depreciation & Amortization |
2.55 M | 2.93 M | 2.7 M | 1.92 M | 903 K | 1.28 M | 1.14 M | 1.37 M | 739 K | 608 K | 523 K | 438 K |
Accounts Payables |
3.34 M | 7.75 M | 5.73 M | 3.14 M | 3.62 M | 1.49 M | 1.44 M | 1.26 M | 1.98 M | 1.82 M | 1.69 M | - |
Accounts Receivables |
6.54 M | 11.4 M | 3.38 M | 3.66 M | 7.37 M | 2.09 M | 3.38 M | 2.42 M | 8.34 M | 4.59 M | 4.82 M | 3 M |
Total Inventories |
7.72 M | 12.9 M | 12.5 M | 9.6 M | 7.85 M | 4.42 M | 3.34 M | 3.58 M | 3.64 M | 3.19 M | 2.49 M | 2.3 M |
All numbers in USD currency
Quarterly Cash Flow Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -9.86 M | - | -4.37 M | - | -24.2 M | - | -7.26 M | - | -14.1 M | -7.33 M | -5.65 M | - | -6.4 M | -7.09 M | -4.75 M | - | -7.53 M | -5.08 M | -2.32 M | - | -7.18 M | -5.46 M | -3.87 M | - | -5.68 M | -3.86 M | - | - | - | - | -942 K | - | - | - | -650 K | - | 584 K | 803 K | 57.4 K | - | 952 K | 1.79 M | 149 K | - | 1.56 M | 926 K | 1.56 M |
Depreciation & Amortization |
- | 1.87 M | - | 599 K | - | 2.19 M | - | 687 K | - | 2.06 M | 1.44 M | 734 K | - | 1.67 M | 750 K | 355 K | - | 663 K | 447 K | 223 K | - | 1.01 M | 774 K | 478 K | - | 876 K | 580 K | 292 K | - | 982 K | 666 K | 346 K | - | 537 K | 344 K | 173 K | - | 446 K | 282 K | 141 K | - | 405 K | 270 K | 130 K | - | 322 K | 217 K | 112 K |
Accounts Payables |
- | 3.07 M | - | 5.62 M | 7.75 M | 5.98 M | 5.9 M | 6.1 M | 5.73 M | 5.73 M | 5.73 M | 5.73 M | 3.14 M | 3.14 M | 3.14 M | 3.14 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 1.49 M | 1.49 M | 1.49 M | 1.49 M | 1.44 M | 1.44 M | 1.44 M | 1.44 M | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 1.98 M | 1.98 M | 1.98 M | 1.98 M | 1.82 M | 1.82 M | 1.82 M | 1.82 M | 1.69 M | 1.69 M | 1.69 M | 1.69 M | 1.26 M | 1.26 M | 1.26 M | - |
Accounts Receivables |
- | 5.25 M | - | 9.88 M | 11.4 M | 6.78 M | 2.98 M | 2.41 M | 3.38 M | 3.38 M | 3.38 M | 3.38 M | 3.66 M | 3.66 M | 3.66 M | 3.66 M | 7.37 M | 7.37 M | 7.37 M | 7.37 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 3.38 M | 3.38 M | 3.38 M | 3.38 M | 2.42 M | 2.42 M | 2.42 M | 2.42 M | 8.34 M | 8.34 M | 8.34 M | 8.34 M | 4.59 M | 4.59 M | 4.59 M | 4.59 M | 4.82 M | 4.82 M | 4.82 M | 4.82 M | 3 M | 3 M | 3 M | 3 M |
Total Inventories |
- | 8.47 M | - | 11.8 M | 12.9 M | 16.8 M | 15.7 M | 14.7 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 7.85 M | 7.85 M | 7.85 M | 7.85 M | 4.42 M | 4.42 M | 4.42 M | 4.42 M | 3.34 M | 3.34 M | 3.34 M | 3.34 M | 3.58 M | 3.58 M | 3.58 M | 3.58 M | 3.64 M | 3.64 M | 3.64 M | 3.64 M | 3.19 M | 3.19 M | 3.19 M | 3.19 M | 2.49 M | 2.49 M | 2.49 M | 2.49 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Chembio Diagnostics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Biomerica
BMRA
|
$ 2.13 | -2.74 % | $ 4.89 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
$ 25.75 | 3.0 % | $ 715 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 195.6 | 0.17 % | $ 21.7 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
$ 65.94 | -1.51 % | $ 25.7 B | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
$ 104.91 | - | $ 19.8 B | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
$ 16.33 | 5.29 % | $ 494 M | ||
|
Charles River Laboratories International
CRL
|
$ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
$ 166.96 | 0.54 % | $ 28.7 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
$ 1.46 | 26.96 % | $ 1.86 M | ||
|
Interpace Biosciences
IDXG
|
$ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
$ 578.51 | 0.22 % | $ 46.5 B | ||
|
Agilent Technologies
A
|
$ 112.02 | 0.65 % | $ 34.1 B | ||
|
Illumina
ILMN
|
$ 123.79 | -0.43 % | $ 19.7 B | ||
|
ICON Public Limited Company
ICLR
|
$ 100.35 | 0.65 % | $ 8.28 B | ||
|
DarioHealth Corp.
DRIO
|
$ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
$ 84.9 | -0.33 % | $ 10.6 B | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
$ 17.56 | 2.39 % | $ 936 M | ||
|
Lantheus Holdings
LNTH
|
$ 75.73 | -0.92 % | $ 5.11 B | ||
|
Celcuity
CELC
|
$ 106.75 | 0.67 % | $ 4.21 B | ||
|
Medpace Holdings
MEDP
|
$ 456.93 | 0.98 % | $ 13.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 264.42 | 0.54 % | $ 22 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
$ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
Myriad Genetics
MYGN
|
$ 4.66 | 1.75 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 3.48 | 0.87 % | $ 1.87 M | ||
|
NeoGenomics
NEO
|
$ 8.1 | 1.76 % | $ 1.04 B | ||
|
National Research Corporation
NRC
|
$ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
$ 200.09 | 2.46 % | $ 19.7 B | ||
|
OPKO Health
OPK
|
$ 1.15 | 2.68 % | $ 798 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.39 | 4.51 % | $ 417 M | ||
|
RadNet
RDNT
|
$ 61.74 | 0.41 % | $ 4.64 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B |